Related references
Note: Only part of the references are listed.Estimates of cancer incidence and mortality in Europe in 2008
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2010)
EAU Guidelines on Renal Cell Carcinoma: The 2010 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Loukas F. Kontovinis et al.
BMC CANCER (2009)
Is Hypothyroidism a Clinically Relevant Toxicity of Tyrosine Kinase Inhibitors?
Francesco Torino et al.
THYROID (2009)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: Implications for the prevalence of subclinical hypothyroidism
Martin I. Surks et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma
TM Mekhail et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)